BACKGROUND: Low CD4 recovery among HIV-positive individuals who achieve virologic suppression is common but has not been studied among individuals initiating treatment at CD4 counts of >500 cells/mm. SETTING: United States, Africa, Asia, Europe and Israel, Australia, Latin America. METHODS: Among participants randomized to immediate antiretroviral therapy (ART) in the Strategic Timing of AntiRetroviral Therapy trial, low CD4 recovery was defined as a CD4 increase of <50 cells/mm from baseline after 8 months despite viral load of ≤200 copies/mL. Risk factors for low recovery were investigated with logistic regression. RESULTS: Low CD4 recovery was observed in 39.7% of participants. Male sex [odds ratio (OR), 1.53; P = 0.007], lower screening CD4 cell counts (OR, 1.09 per 100 fewer cells/mm; P = 0.004), higher baseline CD8 cell counts (OR, 1.05 per 100 more cells/mm; P < 0.001), and lower HIV RNA levels (OR, 1.93 per log10 decrease; P < 0.001) were associated with low CD4 recovery. D-dimer had a quadratic association with low CD4 recovery, with lowest odds occurring at 0.32 μg/mL. At lower HIV RNA levels, the odds of low CD4 recovery were elevated across the levels of screening CD4 count; but at higher HIV RNA levels, the odds of low CD4 recovery were higher among those with lower vs. higher screening CD4. CONCLUSIONS: Low CD4 recovery is frequent among participants starting ART at high CD4 counts. Risk factors include male sex, lower screening CD4 cell counts, higher CD8 cell counts, and lower HIV RNA levels. More follow-up is required to determine the impact of low CD4 recovery on clinical outcomes.

Bern University Hospital University of Bern Bern Switzerland

Charles University Hospital Plzen Czech Republic

Hennepin Healthcare Research Institute Minneapolis MN

Tulane University New Orleans LA

University of Copenhagen Denmark

University of Minnesota Minneapolis MN

University of New South Wales Sydney Australia

Zobrazit více v PubMed

Moore RD, Keruly JC. CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Persons with Sustained Virologic Suppression. Clin Infect Dis. 2007;44(3):441–446. doi:10.1086/510746 PubMed DOI

Lok JJ, Bosch RJ, Benson CA, et al. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS. 2010;24(12):1867–1876. doi:10.1097/QAD.0b013e32833adbcf PubMed DOI PMC

Bouteloup V, Sabin C, Mocroft A, et al. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. HIV Med. 2017;18(1):33–44. doi:10.1111/hiv.12389 PubMed DOI

Mocroft A, Phillips A, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007;370(9585):407–413. doi:10.1016/S0140-6736(07)60948-9 PubMed DOI

Costagliola D, Lacombe J-M, Ghosn J, et al. CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression. J Int AIDS Soc Vol 17, No 4 Suppl 3 2014. http://www.jiasociety.org/index.php/jias/article/view/19481. PubMed PMC

Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy. N Engl J Med. 2013;368(3):218–230. doi:10.1056/NEJMoa1110187 PubMed DOI PMC

Okulicz JF, Le TD, Agan BK, et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1–infected individuals. JAMA Intern Med. 2015;175(1):88–99. 10.1001/jamainternmed.2014.4010. PubMed DOI PMC

Gazzola L, Tincati C, Bellistré GM, d’Arminio Monforte A, Marchetti G. The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options. Clin Infect Dis. 2009;48(3):328–337. doi:10.1086/695852 PubMed DOI

Corbeau P, Reynes J. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood. 2011;117(21):5582 LP–5590. http://www.bloodjournal.org/content/117/21/5582.abstract. PubMed

Gaardbo JC, Hartling HJ, Gerstoft J, Nielsen SD. Incomplete Immune Recovery in HIV Infection: Mechanisms, Relevance for Clinical Care, and Possible Solutions. Clin Dev Immunol. 2012;2012:670957. doi:10.1155/2012/670957 PubMed DOI PMC

Baker JV, Peng G, Rapkin J, et al. Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases. J Acquir Immune Defic Syndr. 2008;48(5):541–546. PubMed PMC

Takuva S, Maskew M, Brennan AT, Long L, Sanne I, Fox MP. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc Vol 17 2014. http://www.jiasociety.org/index.php/jias/article/view/18651/3525. PubMed PMC

INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807. doi:10.1056/NEJMoa1506816 PubMed DOI PMC

Helleberg M, Kronborg G, Larsen CS, et al. Poor CD4 response despite viral suppression is associated with increased non-AIDS-related mortality among HIV patients and their parents. AIDS. 2013;27(6). http://journals.lww.com/aidsonline/Fulltext/2013/03270/Poor_CD4_response_despite_viral_suppression_is.19.aspx. PubMed

Zoufaly A, Cozzi-Lepri A, Reekie J, et al. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS One. 2014;9(1). doi:10.1371/journal.pone.0087160 PubMed DOI PMC

Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 2003;4:255–262. PubMed

Grabar S, Moing V, Goujard C, Al E. CLinical outcome of patients with hiv-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133(6):401–410. 10.7326/0003-4819-133-6-200009190-00007. PubMed DOI

Khanna N, Opravil M, Furrer H, et al. CD4 + T Cell Count Recovery in HIV Type 1–Infected Patients Is Independent of Class of Antiretroviral Therapy. Clin Infect Dis. 2008;47(8):1093–1101. doi:10.1086/592113 PubMed DOI

Rauch A, Nolan D, Furrer H, et al. HLA-Bw4 Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. Clin Infect Dis. 2008;46(12):1921–1925. 10.1086/588479. PubMed DOI

Haas DW, Geraghty DE, Andersen J, et al. Immunogenetics of CD4 Lymphocyte Count Recovery during Antiretroviral Therapy: An AIDS Clinical Trials Group Study. J Infect Dis. 2006;194(8):1098–1107. 10.1086/507313. PubMed DOI

Fernandez S, Rosenow AA, James IR, et al. Recovery of CD4+ T Cells in HIV Patients With a Stable Virologic Response to Antiretroviral Therapy Is Associated With Polymorphisms of Interleukin-6 and Central Major Histocompatibility Complex Genes. JAIDS J Acquir Immune Defic Syndr. 2006;41(1). http://journals.lww.com/jaids/Fulltext/2006/01010/Recovery_of_CD4__T_Cells_in_HIV_Patients_With_a.1.aspx. PubMed

Rajasuriar R, Booth D, Solomon A, et al. Biological Determinants of Immune Reconstitution in HIV‐Infected Patients Receiving Antiretroviral Therapy: The Role of Interleukin 7 and Interleukin 7 Receptor α and Microbial Translocation. J Infect Dis. 2010;202(8):1254–1264. doi:10.1086/656369 PubMed DOI

Hartling HJ, Thørner LW, Erikstrup C, et al. Polymorphism in interleukin-7 receptor α gene is associated with faster CD4+ T-cell recovery after initiation of combination antiretroviral therapy. Aids. 2014;28(12):1739–1748. doi:10.1097/QAD.0000000000000354 PubMed DOI

Babiker AG, Emery S, Fätkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials. 2013;10:S5–S36. doi:10.1177/1740774512440342 PubMed DOI PMC

Sharma S, Babiker AG, Emery S, et al. Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(Suppl. 1):30–36. doi:10.1111/hiv.12231 PubMed DOI PMC

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.

Svärdsudd K, Blomqvist N. A New Method for Investigating the Relation between Change and Initial Value in Longitudinal Blood Pressure Data: I. Description and Application of the Method. Scand J Soc Med. 1978;6(2):85–95. doi:10.1177/140349487800600207 PubMed DOI

Hayes RJ. Methods for assessing whether change depends on initial value. Stat Med. 1988;7(9):915–927. doi:10.1002/sim.4780070903 PubMed DOI

Ederer F Serum cholesterol changes: Effects of diet and regression toward the mean. J Chronic Dis. 1972;25(5):277–289. doi:10.1016/0021-9681(72)90164-6 PubMed DOI

Blomqvist N On the Relation Between Change and Initial Value. J Am Stat Assoc. 1977;72(360):746–749. doi:10.2307/2286454 DOI

Laird NM, Ware JH. Random-Effects Models for Longitudinal Data. Biometrics. 1982;38(4):963–974. doi:10.2307/2529876 PubMed DOI

Gandhi RT, Spritzler J, Chan E, et al. Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects: Results From ACTG 384. J Acquir Immune Defic Syndr. 2006;42(4):426–434. http://journals.lww.com/jaids/Fulltext/2006/08010/Effect_of_Baseline__and_Treatment_Related_Factors.6.aspx. PubMed

Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17(13). http://journals.lww.com/aidsonline/Fulltext/2003/09050/Continued_CD4_cell_count_increases_in_HIV_infected.9.aspx. PubMed

Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS. 2002;16(3). http://journals.lww.com/aidsonline/Fulltext/2002/02150/The_extent_of_HIV_1_related_immunodeficiency_and.7.aspx. PubMed

Asmelash A, Zheng Y, Kaloustian KW, et al. Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa. BMC Infect Dis. 2014;14(1):1–7. doi:10.1186/1471-2334-14-331 PubMed DOI PMC

Estes J, Baker JV, Brenchley JM, et al. Collagen Deposition Limits Immune Reconstitution in the Gut. J Infect Dis. 2008;198(4):456–464. doi:10.1086/590112 PubMed DOI PMC

Schacker T The role of secondary lymphatic tissue in immune deficiency of HIV infection. Aids. 2008;22(SUPPL. 3):13–18. doi:10.1097/01.aids.0000327511.76126.b5 PubMed DOI

Engsig FN, Zangerle R, Katsarou O, et al. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clin Infect Dis. 2014;58(9):1312–1321. doi:10.1093/cid/ciu038 PubMed DOI PMC

Engsig FN, Gerstoft J, Kronborg G, et al. Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: A cohort study. BMC Infect Dis. 2010;10(1):318. doi:10.1186/1471-2334-10-318 PubMed DOI PMC

Baker JV, Sharma S, Grund B, et al. Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. Open Forum Infect Dis. 2017;4(1):1–9. doi:10.1093/ofid/ofx262 PubMed DOI PMC

Maini MK, Gilson RJ, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med. 1996;72(1):27–31. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1195587/. PubMed PMC